Form 4: Acrivon Therapeutics Executive Acquires Shares

Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, Inc., acquired 38,584 shares of common stock.

Summary

• Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, Inc., acquired 38,584 shares of common stock on May 18, 2026.
• These shares were acquired as restricted stock units (RSUs).
• Vesting for these RSUs is scheduled, with 16.67% vesting on November 18, 2026, and the remainder vesting in 10 equal quarterly installments thereafter, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard executive compensation and retention mechanism rather than a significant new development or financial event.

Positives

• Acquisition of shares by a key executive can signal confidence in the company's future prospects.
• The executive's continued service through vesting dates indicates commitment to the company.

Negatives

• The acquisition is in the form of RSUs, which are subject to vesting conditions, meaning the executive does not have immediate full ownership.
• The filing does not provide details on the price paid for these RSUs, only that the acquisition amount was $0, suggesting they were granted as compensation.

Risks

• The vesting schedule introduces a risk that the executive may not remain with the company until all RSUs vest.
• Future stock price performance will impact the ultimate value of these RSUs for the executive.

Future Outlook

The vesting schedule for the RSUs indicates a phased release of shares over time, contingent on continued employment, suggesting a long-term outlook for the executive's involvement.

Industry Context

StockSavvy.ai notes that insider acquisitions of stock, particularly in the form of RSUs with vesting schedules, are common in the biotechnology sector as a means of executive compensation and retention, aligning executive interests with long-term company performance.

Stakeholder Impact

• Shareholders: The acquisition by a key executive may be viewed positively as a sign of commitment, but it does not represent new capital for the company or a change in outstanding shares.
• Employees: The RSU structure highlights a common compensation practice for executives, potentially influencing employee expectations.
• Management: Reinforces the executive's role and long-term incentive alignment.

Next Steps

• Continued service by Erick Gamelin through the specified vesting dates.
• Vesting of RSUs according to the schedule: 16.67% on November 18, 2026, and the remainder in 10 quarterly installments thereafter.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Restricted Stock Units, RSU, Erick Gamelin, Chief Development Officer, Securities Ownership